Skip to content
Screener

Recursion Pharmaceuticals, Inc. RXRX Contract With Customer Asset Net Current

Contract With Customer Asset Net Current at other companies

Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$5.3M-10.2%
SLD
Solid PowerSLDP
$8.48M+282%
CVS Health logo
CVS HealthCVS
$12.99B+24.1%
Eos Energy Enterprises, Inc. logo
Eos Energy Enterprises, Inc.EOSE
$15.88M+8.7%
Brink's, Inc. logo
Brink's, Inc.BCO
$10.7M+42.7%
Regal Rexnord logo
Regal RexnordRRX
$127.1M

Other financials

Income statement

See full
Revenue$7.7M-60.1%
Gross profit-$3.8M-307%
Operating income-$135.0M+23.4%
Net income-$131.0M+23.8%
EPS (diluted)-$0.25+39.0%

Balance sheet

See full
Cash & equivalents$556.8M+4.3%
Total debt$80.5M-27.2%
Total equity$915.0M-0.5%
Total assets$1.2B-6.9%

Cash flow

See full
Operating cash flow-$105.9M-38.6%
CapEx$44.0K-98.6%
Free cash flow-$106.0M-33.2%

Valuation

See full
Market cap$1.7B-28.6%
Enterprise value$1.22B-37.5%
P/S31×-5.9×

Profitability

See full
Gross margin3.5%
Operating margin-991.7%-13.7pp
Net margin-945.9%-52.4pp
FCF margin-642.2%+36.1pp

Returns & leverage

See full
Return on equity-56.6%-14.5pp
Debt / equity0.1×0.0×
Current ratio+1.5×

Where this comes from

Reported directly by Recursion Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerAssetNetCurrent.

The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 6:32 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001601830-26-000098

Of the revenue recognized during the three and six months ended June 30, 2026, $7.0 million and $11.4 million was included in the unearned revenue balance as of December 31, 2025. Of the revenue recognized during the three and six months ended June 30, 2025, $15.4 million and $30.2 million was included in the unearned revenue balance as of December 31, 2024, respectively. Revenue recognized was from the upfront and variable consideration payments received from the related contracts, which decreased the aggregate unearned revenue recognized. As of June 30, 2026, the Company had $5.3 million of costs incurred to fulfill a contract on its Condensed Consolidated Balance Sheet within “Other Current Assets.”

Item 1. Financial Statements (unaudited)

FAQ

What is Recursion Pharmaceuticals, Inc.'s contract with customer asset net current?
Recursion Pharmaceuticals, Inc. (RXRX) reported contract with customer asset net current of $5.3M in Q2 2026.
How has Recursion Pharmaceuticals, Inc.'s contract with customer asset net current changed year-over-year?
Recursion Pharmaceuticals, Inc.'s contract with customer asset net current decreased by 10.2% year-over-year, from $5.9M to $5.3M.
What does contract with customer asset net current mean?
Contract With Customer Asset Net Current as reported by Recursion Pharmaceuticals, Inc. Class A Common Stock.

Ask your AI about Recursion Pharmaceuticals, Inc.'s contract with customer asset net current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude